Dianthus Therapeutics' Chief Financial Officer sold 8,224 shares of the company, generating approximately $739,000 from the transaction. This insider sale could indicate the CFO's personal financial decision or a strategic move, but it may raise questions among investors about the company's near-term prospects. Investors should watch for any further insider activity or company updates that clarify the reasons behind this sale.
The iShares 20+ Year Treasury Bond ETF (TLT) saw $122 million in outflows last week amid rising US bond yields driven by higher inflation and hawkish Federal Reserve signals. April's inflation data showed consumer prices jumping to 3.8% and producer ...
Canada has lost over 112,000 jobs in 2026, with Quebec hit hardest, losing 91,000 jobs. Full-time employment is declining sharply, youth unemployment is up to 14.3%, and living costs remain high despite official inflation claims. Entrepreneur Yanik G...
Stock and oil futures are expected to start trading on Sunday ahead of key earnings reports from Nvidia and Walmart this week. The market activity follows President Donald Trump's return from a trip to China, with tensions involving Iran also influen...
With SpaceX's IPO expected soon, investors have multiple regulated fund options to gain exposure before the public listing. However, these vehicles differ significantly in fees, liquidity, valuation transparency, and how gains are passed through. Key...
Nvidia's earnings report this week is highly anticipated, with analysts expecting strong results driven by GPU demand and AI growth, but a beat-and-raise is needed to justify further stock gains. Other major companies like Walmart, Target, and Home D...
